PDGFRB is altered in 3.04% of non-small cell lung carcinoma patients with PDGFRB Amplification present in 0.03% of all non-small cell lung carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 5 clinical trials for non-small cell lung carcinoma, of which 3 are open and 2 are closed. Of the trials that contain PDGFRB Amplification and non-small cell lung carcinoma as inclusion criteria, 5 are phase 2 (3 open) [5].

PDGFRB is altered in 1.91% of adenocarcinoma of the gastroesophageal junction patients with PDGFRB Amplification present in 0.67% of all adenocarcinoma of the gastroesophageal junction patients [4].

PDGFRB Amplification is an inclusion criterion in 2 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB Amplification and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 2 (2 open) [5].

PDGFRB is altered in 2.28% of cancer patients with PDGFRB Amplification present in 0.09% of all cancer patients [4].

PDGFRB Amplification is an inclusion criterion in 2 clinical trials for cancer, of which 1 is open and 1 is closed. Of the trials that contain PDGFRB Amplification and cancer as inclusion criteria, 2 are phase 2 (1 open) [5].

PDGFRB is altered in 1.05% of pancreatic carcinoma patients with PDGFRB Amplification present in 0.04% of all pancreatic carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PDGFRB Amplification and pancreatic carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

PDGFRB is altered in 3.27% of colorectal carcinoma patients with PDGFRB Amplification present in 0.41% of all colorectal carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for colorectal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and colorectal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.7% of ovarian carcinoma patients with PDGFRB Amplification present in 0.2% of all ovarian carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for ovarian carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and ovarian carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.23% of bile duct carcinoma patients with PDGFRB Amplification present in 0.12% of all bile duct carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.39% of malignant solid tumor patients with PDGFRB Amplification present in 0.1% of all malignant solid tumor patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant solid tumor, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant solid tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.33% of hepatobiliary neoplasm patients with PDGFRB Amplification present in 0.07% of all hepatobiliary neoplasm patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.33% of malignant hepatobiliary neoplasm patients with PDGFRB Amplification present in 0.07% of all malignant hepatobiliary neoplasm patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant hepatobiliary neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant hepatobiliary neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 6.99% of melanoma patients with PDGFRB Amplification present in 0.05% of all melanoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for melanoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and melanoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.43% of soft tissue sarcoma patients with PDGFRB Amplification present in 0.05% of all soft tissue sarcoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and soft tissue sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.42% of breast carcinoma patients with PDGFRB Amplification present in 0.04% of all breast carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 3.06% of lung carcinoma patients with PDGFRB Amplification present in 0.03% of all lung carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.71% of malignant uterine neoplasm patients with PDGFRB Amplification present in 0.03% of all malignant uterine neoplasm patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.59% of bladder carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.26% of cervical carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.96% of diffuse intrinsic pontine glioma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for diffuse intrinsic pontine glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and diffuse intrinsic pontine glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.12% of esophageal carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and esophageal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.72% of esophageal squamous cell carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.02% of gallbladder carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.79% of gastric adenocarcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.77% of gastric carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 0.57% of gastrointestinal stromal tumor patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.55% of head and neck carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 0.58% of lip and oral cavity carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for lip and oral cavity carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and lip and oral cavity carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.63% of malignant glioma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.43% of malignant laryngeal neoplasm patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant laryngeal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant laryngeal neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.25% of malignant salivary gland neoplasm patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for malignant salivary gland neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and malignant salivary gland neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.38% of multiple myeloma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for nasal cavity and paranasal sinus carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and nasal cavity and paranasal sinus carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.08% of nasopharyngeal carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for nasopharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and nasopharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.61% of oropharyngeal carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for oropharyngeal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and oropharyngeal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 3.6% of small cell lung carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PDGFRB Amplification and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) [5].

PDGFRB is altered in 3.06% of urothelial carcinoma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 1.53% of WHO grade II glioma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for WHO grade II glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and WHO grade II glioma as inclusion criteria, 1 is phase 2 (1 open) [5].

PDGFRB is altered in 2.68% of WHO grade III glioma patients [4].

PDGFRB Amplification is an inclusion criterion in 1 clinical trial for WHO grade III glioma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB Amplification and WHO grade III glioma as inclusion criteria, 1 is phase 2 (1 open) [5].